To potentially translate our findings to a realistic strategy in the clinic for the treatment of EGFRm NSCLC relapsed from osimertinib treatment, we further screened several small molecule TRPM2 inhibitors or inhibitors with TRPM2‐inhibitory activity[6] including N‐(p‐amylcinnamoyl)anthranilic acid (ACA),[6, 24] JNJ‐28583113,[25] ZA‐10, ZA‐18,[26] D9,[27] econazole, clotrimazole, 2‐APB, FFA, 12‐deacetylscalaradial and carvacrol for their abilities to synergize with osimertinib in decreasing the survival of osimertinib‐resistant cells. Here, TRPM2 is linked to non-small cell lung carcinoma.